hydroxyurea + paclitaxel

A chemotherapy regimen combining hydroxyurea and paclitaxel, studied primarily in head and neck cancers and non-small cell lung cancer. It is often investigated with additional agents like 5-fluorouracil (5-FU) and radiation therapy. The rationale for this combination includes hydroxyurea's potential to reverse chemotherapy resistance by disrupting double minute chromosomes and paclitaxel's ability to act as a radiosensitizer. This regimen has demonstrated modest activity as second-line treatment for non-small cell lung cancer and has shown promising complete response rates in head and neck cancer when combined with other therapies, despite notable toxicities.